Skip to main content
. 2022 Mar 28;27(Suppl 1):S17–S18. doi: 10.1093/oncolo/oyac014

Table 1.

Event-free survival by neoadjuvant and adjuvant therapy in early-stage TNBC

Endpoint Pembrolizumab (n = 784) Placebo (n = 390) HR (95% CI) p value
EFS events 15.7% 23.8% 0.63 (0.48-0.82) .00031
EFS at 36 months 84.5% 76.8%

Abbreviations: CI, confidence interval; EFS, event-free survival; HR, hazard ratio; TNBC, triple-negative breast cancer.